141978-61-2

Basic information

• Product Name: (S)-2-AMINOBUTANAMIDEHCL
• Synonyms: (S)-2-Aminobutanamide HCl
• CAS NO: 141978-61-2
• Molecular Formula: C4H11ClN2O
• Molecular Weight: 138.6
• Mol File: 141978-61-2.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-2-AMINOBUTANAMIDEHCL(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMINOBUTANAMIDEHCL(141978-61-2)
• EPA Substance Registry System: (S)-2-AMINOBUTANAMIDEHCL(141978-61-2)

Safety Data

• Hazardous Substances Data: 141978-61-2(Hazardous Substances Data)

Usage

General Description

(S)-2-Aminobutanamide HCL is a chemical compound that consists of a amide group and an amino group attached to a butane chain. It is commonly used in pharmaceutical and research applications due to its potential as a building block for creating new compounds and drugs. The HCL form is the hydrochloride salt of the compound, which is commonly used to improve the solubility and stability of the compound in aqueous solutions. This chemical has the potential to be used in the development of new drugs for various medical conditions, and its properties make it a valuable tool in the fields of chemistry and biology.

Upstream product

• 7682-18-0 (S)-2-aminobutyric acid methyl ester hydrochloride 
• 53726-14-0 DL-2-aminobutanamide 
• 87-69-4 L-Tartaric acid 
• 2483-62-7 (S)-2-aminobutyric acid methyl ester 
• 868134-59-2 L-2-aminobutanamide tartaric acid 
• 945472-53-7 (S)-2-aminobutyramide D-mandelic acid salt 
• 7324-11-0 (S)-2-amino-butanamide 
• 148528-89-6 tert-butyl N-[(1S)-1-carbamoylpropyl]carbamate 
• 1386992-24-0 (±)-2‐((benzylidene)amino)butanamide 
• 40651-89-6 2-aminobutyronitrile 

Downstream Products

• 123952-17-0 Boc-Tyr-Abu-NH₂ 

Relevant articles and documents

A Viedma ripening route to an enantiopure building block for Levetiracetam and Brivaracetam

A simple route to enantiomerically pure (S)-2-aminobutyramide-the chiral component of the anti-epileptic drugs Levetiracetam and Brivaracetam has been developed. This approach is based on the rational design and application of a Viedma ripening process. The practical potential of the process is demonstrated on a large scale.

Preparation method of L-2-aminobutanamide hydrochloride

The invention relates to the technical field of preparation of chiral drug intermediates, and discloses a preparation method of L-2-aminobutanamide hydrochloride, which comprises the following steps: dropwise adding ethyl 2-bromobutyrate into stronger ammonia water, and carrying out chemical reaction in a closed container to prepare a prefabricated mixture; According to the preparation method of the L-2-aminobutanamide hydrochloride, ethyl 2-bromobutyrate is used as an initial raw material, and the medical intermediate L-2-aminobutanamide hydrochloride is prepared through ammonolysis and chiral resolution. Compared with the traditional preparation method, the preparation method adopts a chiral reagent (+)-mandelic acid with low raw material price and racemic 2-aminobutanamide hydrochloride to form diastereoisomers, the L-2-aminobutanamide hydrochloride is obtained through resolution by utilizing the difference of the dissolving properties of the diastereoisomers in ethanol, the optical purity and the chemical purity of the product are high, and the technical scheme has the advantages of mild reaction conditions, short reaction steps, high yield, stable product quality and easy realization of industrial production.

Method for preparing levetiracetam

The invention relates to a method for preparing levetiracetam. The method comprises the following steps: reacting aminobutyric acid in lower alcohol and thionyl chloride to obtain an intermediate I; adding ammonia water to continue the reaction, and adding hydrochloric acid to adjust the pH value to about 3 to salify to obtain a salified intermediate II refined product; reacting the intermediate II in the presence of KOH in the presence of a catalyst and dichloromethane, and then adding 4-chlorobutyryl chloride to continuously react; adding water to hydrolyze, adjusting the pH to be weakly alkaline by using diluted hydrochloric acid, and crystallizing to obtain a levetiracetam crude product; decolorizing and crystallizing in ethyl acetate to obtain a refined product of levetiracetam. The invention also relates to the levetiracetam prepared by the method and pharmaceutical application thereof, for example, the levetiracetam can be used for treating or preventing epilepsy, Parkinson's disease, dyskinesia, migraine, tremor, idiopathic tremor, bipolar disorder, chronic pain, neuropathic pain, or bronchial, asthma or allergic diseases.